Introduction
Non-small cell lung carcinoma (NSCLC) is the most common form of lung cancer and the leading cause of cancer-related deaths worldwide. NSCLC has a 5-year survival rate of only 15% due in part to advanced disease at diagnosis and high rates of metastases. A subset of NSCLC's acquire increased copy number or gain-of-function mutations in EGF receptor (EGFR) leading to constitutive EGFR signaling to pathways controlling cell growth, survival, and motility (1) . EGFR is a known driver of NSCLC as transgenic mice with inducible expression of mutant alleles of EGFR (e.g., D747-752 or L858R) in type II lung pneumocytes develop lung adenocarcinomas that regressed upon treatment with an EGFR inhibitor (2) . Indeed, patients with lung cancer with activating EGFR mutations who are treated with EGFR inhibitors frequently show a positive initial response but eventually relapse due to development of resistance (3) . Therefore, identifying new targets for molecular-targeted therapies and development of combinational therapies may lead to improved NSCLC patient outcomes.
Fer (Fes-related) is a widely expressed nonreceptor tyrosine kinase that is activated downstream of EGFR (4) , and was recently reported to promote resistance to quinacrine (5) , an antimalarial drug with potential as a cancer therapeutic (6) . Fer is composed of 4 domains: F-BAR (Fer/CIP4 homology-Bin/amphiphysin/RVS), FX (extended F-BAR), SH2 (Src homology 2), and a protein-tyrosine kinase domain. F-BAR domains form crescent-shaped dimers that bind phosphoinositides that are enriched in membrane microdomains at sites of endocytosis and filamentous actin (F-actin) polymerization (7) . The F-BAR domains of Fer and Fes, a more tissue-restricted family member (8) , were initially shown to bind PI(4,5)P 2 (9, 10) . More recently, the FX domain in Fer was shown to bind phosphatidic acid (PA), leading to enhanced Fer kinase activity and localization to lamellipodia (11) . Itoh and colleagues also show that Fer promotes cell motility in a phospholipase D (PLD)/PAdependent pathway (11) . Recently, Fes was also shown to bind phosphatidic acid and participate in a PLD-induced pathway of myeloid differentiation (12) . The SH2 domain of Fer confers binding to tyrosine-phosphorylated proteins, including receptor tyrosine kinases [e.g., EGFR, plateletderived growth factor receptor (PDGFR), etc.], adaptor proteins (e.g., cortactin, Gab1, etc.), and immune receptors (8) . Recently, the structure of the SH2-kinase domain fragment of Fes was solved, and this revealed a critical interface allowing allosteric regulation between the SH2 and kinase domains (13) . The implications of this study are that Fes kinase activation occurs only upon ligand binding to its SH2 domain. Because of conservation of these critical interface residues between Fer and Fes, it is likely that Fer kinase activation also requires the SH2 domain to be bound to ligands such as EGFR.
A number of studies have identified Fer activation or upregulation in a number of different cancers, including lung (14) , hepatic (15) , prostate (16) , and triple-negative breast cancer (17) . Overexpression of Fer was also linked to quinacrine resistance and enhanced activation of NFkB pathway (5) . Other Fer substrates are linked to tumor progression and metastasis. The transcription factor STAT3 is a known substrate of Fer, and has been linked to prostate tumor progression (16) . The actin regulatory protein cortactin is a substrate of Fer downstream of growth factor receptors and integrins (18) (19) (20) . Recent studies also implicate Fer in signaling via Rac GTPase to promote lamellipodia formation and cell motility (11) . Overexpression of Fer also correlated with enhanced tyrosine phosphorylation of Vav2 (11), a Rac guanine exchange factor (GEF) that is activated via tyrosine phosphorylation downstream of EGFR (21) . Fer may also promote Rac activation by phosphorylating RhoGDIa to limit Rac1 binding (22) , and prevent sequestration by RhoGDIa (23) .
In this report, we show that Fer is expressed in normal lung tissue, primarily in type II pneumocytes, and at elevated levels in NSCLC (adenocarcinoma and squamous subtypes). EGF treatment of H1299 lung adenocarcinoma cells led to rapid Fer activation and localization to leading edge membrane projections. Fer silencing reduced lamellipodia formation, motility, and cell invasion via defects in the Vav2/Rac signaling axis. Stable silencing of Fer also reduced spontaneous metastases in subcutaneous tumor xenograft assays in mice. Together, these findings identify Fer as a positive regulator of EGFRinduced lamellipodia formation, cell motility, invasion, and tumor metastasis.
Materials and Methods
Cell culture, transfections, and EGF treatment NCI-H1299 were purchased from American Type Culture Collection and were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FBS (Sigma-Aldrich), 1% glutamine (Invitrogen), and 1% antimycotic/antibiotics (Invitrogen) at 37 C in a 5% CO 2 atmosphere. A549 cells were acquired from Dr. Susan Cole (Queen's University, Kingston, ON, Canada) and grown in 5% FBS as earlier. Immortalized wild-type (WT; fer þ/þ ) and fer-deficient (fer DR/DR ) mouse embryonic fibroblasts (MEF) were described previously (19, 20) . Transient transfections of cells with plasmid DNA were conducted using FuGENE HD (Roche Diagnostics Inc.) or X-tremeGENE (Roche Applied Science) according to the manufacturer's directions. EGF stimulation of H1299 cells were conducted by starving overnight in serum-free media (16 hours) before treatment with human EGF (50 or 100 ng/mL; Peprotech) for indicated times in figure legends. EGF stimulation of MEF cells was conducted by starving in serum-free media for 48 hours before treatment with human EGF (100 ng/mL for 5 minutes).
Generation of stable Fer knockdown cell lines
pGIPZ-based lentiviral transfection encoding a nontargeting short hairpin RNA (shRNA) and Fer-specific shRNA (FerKD1: 5 0 -CTATCCAAATTTGAATCTA-3 0 , FerKD2: 5 0 -AGGCTCACCATGATGATTA-3 0 ) were obtained from Open Biosystems. Lentiviral plasmids were cotransfected with packaging and envelope plasmids (CMVDR8.91 and MD.2G) in HEK 293T human embryonic kidney cells and viral supernatants collected at 48 hours. H1299 and A549 cells were transduced with the above viruses and stable cell pools were selected after 48 hours in media with puromycin (2 mg/mL). Cell pools were passaged several times and lysates prepared to test the efficiency of Fer silencing by immunoblotting.
Immunoprecipitation and immunoblotting
For immunoprecipitation assays, cells were lysed in Mg2þ lysis buffer [50 mmol/L Tris-HCL (pH 7.4), 150 mmol/L NaCL, 1% Triton X-100, 0.25% sodium deoxycholate, 10% glycerol, 25 nmol/L NaF, 10 mmol/L MgCl 2 , 1 mmol/L EDTA, 10 mg/mL aprotinin, 10 mg/mL leupeptin, 1 mmol/L Na 3 VO 4 , and 100 mmol/L phenylmethylsulfonyl fluoride] and soluble cell lysates (SCL) were subjected to immunoprecipitation with rabbit antiFer (24) antibodies or mouse anti-Vav2 antibodies (Santa Cruz Biotechnology; H-200), and recovered with 25 mL of GammaBind Sepharose (50% v/v slurry in PBS), per 1 mL SCL. After extensive washing, the immune complex was subjected to SDS-PAGE as described later.
For immunoblot assays, cells were lysed using kinase lysis buffer [20 mmol/L Tris-HCL (pH 7.5), 150 nmol/L NaCl, 1 mmol/L EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 10 mg/mL aprotinin, 10 mg/mL leupeptin, 1 mmol/L Na 3 VO 4 , 100 mmol/L phenylmethylsulfonyl fluoride]. Cell lysates were separated by SDS-PAGE under reducing conditions and transferred to Immobilon P membranes (Millipore) using a semi-dry transfer apparatus (Bio-Rad). Membranes were blocked in either 5% bovine serum albumin (BSA) for antiphosphotyrosine antibodies (pY99), or 5% nonfat milk for all other antibodies and then probed with antibodies directed against: Fer (1:1,000; ref. 24) , p-Tyr (1:1,000; Santa Cruz Biotechnology; PY99), tubulin (1:1,000; Sigma; T6074), actin (1:1,000; Santa Cruz Biotechnology; C4), Vav2 (1:1,000; Santa Cruz Biotechnology; H-200), phospho-172 Vav2 (1:1,000; ECM Biosciences), Rac1 (1:1,000; Millipore; 23A8), active Rac1-GTP (1:1,000; NewEast Biosciences), and transferrin (1:1,000; Invitrogen; H68.4) overnight at 4 C. Antibody-antigen complexes were detected using either horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin (1:10,000; GE Healthcare) or HRP-conjugated goat anti-rabbit immunoglobulin (1:10,000; GE Healthcare) and followed by enhanced chemiluminescence (ECL; Applied Biological Materials).
Immunofluorescence staining and confocal microscopy
Immunofluorescence staining was conducted on serumstarved H1299 cells plated on fibronectin (20 ng/mL)-coated coverslips, and treated with EGF (50 ng/mL) for the times indicated in figure legends. Cells were incubated with mouse anti- 
Analysis of Fer expression in NSCLC cell lines and tumor homogenates
Fer expression was analyzed in a panel of normal lung epithelial (NL20) and NSCLC cell lines (NCI-H1299, A549, NCI-H1975, HCC-827, SK-LuCi-6, QU-DB, and LC-T; described in ref. 25) . Tumor and adjacent normal lung tissues were acquired from the Ontario Tumor Bank (Ontario Institute for Cancer Research, Toronto, ON, Canada). These biopsies were collected at initial diagnosis of 12 patients with NSCLC (ages, 48-75 years; grade 2-3). Homogenates were prepared and along with cell lysates above, were subjected to immunoblot with Fer and actin antibodies.
Cell growth assays
Cell growth assays were conducted on H1299 control and Fer knockdown (KD) cells grown to 80% confluence. Cells were trypsinized, fixed in 70% ethanol overnight at 4 C, and treated with 0.1 mg/mL RNaseA in PBS for 30 minutes at room temperature. Cells were permeabilized with PBS with 0.5% Triton X-100 and resuspended in propidium iodide (PI; 10 mg/mL)/RNase A (0.1 mg/mL) at 37 C for 20 minutes. Samples were analyzed by flow cytometry.
Cell migration assays
Wound-healing assays were conducted on confluent monolayers of H1299 and A549 cells (nontargeting and Fer knockdown) that were serum-starved overnight before forming a wound using a pipette tip and removal-suspended cells. Cells were stimulated with media supplemented with EGF (50 ng/mL) and phase contrast micrographs acquired (0 hours). After 18 to 24 hours of incubation, cells were fixed in 4% paraformaldehyde and stained with crystal violet and images were taken at the same positions taken at 0 hours. Cell migration was quantified as the difference between cell-free areas at time 0 and 18 hours for the same field of view. Agarose drop chemotaxis assays were conducted as previously described with minor alterations (26) . Coverslips were coated with fibronectin (20 ng/mL) for 24 hours at room temperature before adding an agarose drop (0.1% low-melting temperature agarose) supplemented with EGF (final concentration of 20 ng/mL). H1299 cells (20,000) were stained with either CellTracker orange or CellTracker green (Invitrogen; 10 mmol/L) for 1 hour before plating on coverslips and allowed to adhere for 6 hours at 37 C. Postadherence images from the edge of the agarose drop were acquired by the Quorum Wave FX microscope (Â10 objective) every 10 minutes for 18 hours in a chamber heated to 37 C in a 5% CO 2 atmosphere. Migration analysis was conducted using the manual tracking suite in ImageJ (NIH, Bethesda, MD, USA).
Invasion assays
Boyden chamber invasion assays were conducted using Transwell inserts (8 mm; BD Biosciences) coated with 17 mL of growth factor-reduced Matrigel (BD Biosciences) that were allowed to solidify at 37 C for 30 minutes. The inserts were placed in a 24-well plate containing DMEM supplemented with 10% FBS and 50,000 H1299 cells in DMEM with 0.5% FBS were plated into the upper chamber. For assays with A549 cells, TGF-b1 (2 ng/mL) was included to increase their invasive potential. After 48 hours for A549 and 60 hours for H1299 cells, the filters were fixed in 4% paraformaldehyde, Matrigel from the upper chamber was removed and filters were stained with DAPI. Epifluorescence was used to detect nuclei of cells that had invaded and image fields were scored using Image Pro Plus software (Media Cybernetics).
Vav2 constructs and in vitro kinase assays
Plasmids encoding Vav2 glutathione S-transferase (GST) fusions with different point mutations were obtained from 
Tumor xenograft assays
Rag2
:gc À/À mice (BALB/c background) are deficient in NK/B/T cells and recently shown to be an excellent model for detecting lung metastases (27) . All experiments were approved by the Queen's University Animal Care Committee. H1299 nontargeting and Fer knockdown cells were grown to 80% to 90% confluence, trypsinized and counted. For xenografting assays, cells were injected subcutaneously into the flank area of the mice ((2.5 Â 10 6 cells in 100 mL). After 5 weeks, mice were sacrificed and tumor masses were recorded. The tumor and lung tissues were resected, fixed in formalin, and embedded in paraffin. Paraffin blocks were serially sectioned and stained with hematoxylin and eosin for histologic examination. Three sections, spaced 25 mm apart, from each mouse were digitally scanned and metastatic nodules were manually scored in a blinded fashion.
Tumor tissue microrrays and immunohistochemistry
Tissue microarrays covering a range of lung cancer types (LC1005; US Biomax) were stained using the VMSI Discovery XT Automated Immunostainer (Ventana Medical Systems, Inc.). Antigens were retrieved with EDTA (pH 8) solution and incubated with mouse anti-Fer (Selleck; 5D2C4; diluted 1:100 in TBS/1% BSA). As a control for specificity, an aliquot of mouse anti-Fer that was precleared with beads containing GST-Fer-FX domain that overlaps the antigenic region (amino acids 280-474) was also used. Immunohistochemistry (IHC) signals were developed using biotinylated goat anti-mouse secondary antibody followed by 3,3 0 -diaminobenzidine (DAB) and hematoxylin counterstained. Tissue microarrays were digitally scanned and were scored using ImageScope software (Aperio) to calculate H scores according to the formula H ¼ (% negative Â 0) þ (% weak positive Â 100) þ (% positive Â 200) þ (% strong positive Â 300), as described in ref. (28) .
Statistical and image analysis
Statistical significance ( Ã , P 0.05) was determined using paired Students t test in Microsoft Excel. Graphs were generated using GraphPad Prism. ImageJ image-analysis software with the manual tracking package was used for quantification analysis of cell migration.
Results

Expression of Fer kinase in normal human lung tissue and NSCLC tumors
To evaluate Fer expression in normal lung and NSCLC tumors, we surveyed Fer levels in NSCLC tumors and matched normal lung tissue homogenates by immunoblot. Although Fer was expressed in all samples, we observed increased Fer protein levels in most tumors (T) compared with their normal (N) lung tissue controls ( Fig. 1A; 2.2 AE 0.4 (mean AE SEM) for T:N ratio; actin served as a loading control). To visualize Fer expression in these tissues, we first established optimal immunohistochemical staining conditions ( Supplementary Fig. S1 ). Importantly, antisera depletion using a recombinant Fer construct (FX domain region) abrogated the immunohistochemical signal ( Supplementary  Fig. S1 ). Next, we conducted Fer immunohistochemical staining in NSCLC tumor tissue microarrays with matching normal adjacent lung tissue. Fer expression was detectable in normal lung tissues, with highest expression in type II pneumocytes that secrete surfactant ( Fig. 1B ; see arrows within insets). Fer was highly expressed in NSCLC tumors, including most adenocarcinomas and squamous carcinomas (Fig. 1B) . Quantification of the immunohistochemical staining (H score) revealed a significant increase in Fer levels in adenocarcinomas or squamous carcinomas compared with normal adjacent lung tissue (Fig. 1C) . Together, these results are consistent with high Fer expression in human lung tumors. 
EGFR-induced Fer activation and localization to lamellipodia in NSCLC cells
To identify potential cell models to test Fer signaling and function, a panel of human lung epithelium-derived cell lines was screened for Fer expression. This panel included an immortalized, normal lung epithelial cell lines (HBE154, HBE158, and NL20), and 6 NSCLC cell lines. Fer immunoblot analysis revealed expression of Fer in normal lung epithelial cell lines, and all NSCLC cell lines tested (Fig. 2A) . Because previous studies have implicated Fer in signaling downstream of EGFR (4, 5), we selected H1299 lung adenocarcinoma cells that express WT EGFR, and effectively model EGFR-driven metastasis in mice (29, 30) .
To test for EGF-induced activation of Fer in H1299 cells, serum-starved cells were treated with or without EGF for 5 minutes. Following immunoprecipitation of Fer from SCLs, tyrosine phosphorylation (pY) of Fer was assessed by immunoblot. We observed increased Fer pY in EGF-treated cell lysates, consistent with increased EGFR pY in SCLs ( Fig. 2B ; see arrow at 170 kDa). Because we observed equal recovery of Fer in the immunoprecipitations (Fig. 2B, bottom) , we conclude that Fer signals downstream of EGFR in H1299 NSCLC cells.
Fer was recently shown to localize to lamellipodia via Nterminal F-BAR/FX domains that bind the PLD product phosphatidic acid and enhance Fer kinase activation (31) . To test whether EGFR signaling alters Fer localization in NSCLC, H1299 cells were plated on poly-L-lysine/fibronectin-coated coverslips, serum-starved, and treated with or without EGF for 5 minutes. Immunofluorescence staining for Fer along with staining of filamentous (F)-actin and nuclei was conducted before confocal microscopy. In serumstarved H1299 cells, Fer localized within the cytosol (green), and displayed no localization to cortical F-actin (red) or the cell nucleus (Fig. 2C, top) . Upon EGF treatment, H1299 cells acquired a migratory phenotype featuring a leading edge with broad lamellipodial protrusions (Fig. 2C, bottom) . Interestingly, Fer was enriched within F-actin-rich regions of the lamellipodia (Fig. 2C, see arrows) . Together, these results are consistent with EGF-induced Fer activation and localization to the leading edge of NSCLC cells undergoing dynamic F-actin polymerization and membrane protrusions.
Stable silencing of Fer impairs EGF-induced lamellipodia formation in H1299 NSCLC
To probe the function of Fer in NSCLC cells, we selected H1299 cell pools transduced with lentiviruses encoding either a nontargeting shRNA control or shRNAs specific for Fer. Fer expression was analyzed following several cell passages, and this revealed efficient Fer knockdown with shRNA1 (KD1) and shRNA2 (KD2) compared with nontargeting control (Fig. 3A) . Densitometry analysis for several cell passages revealed a stable reduction in Fer levels (relative to tubulin) by approximately 80% and 60% in Fer KD1, KD2 cell lysates, respectively.
To test whether Fer silencing affects growth of H1299 cells, the cell-cycle profiles of nontargeting and Fer knockdown cells were compared. Following PI staining of subconfluent H1299 nontargeting and Fer knockdown cells grown in presence of serum, the DNA content of cells was analyzed by flow cytometry. No significant differences were observed for the percentage of cells residing in G 1 , S, or G 2 -M phases of the cell cycle between nontargeting, Fer KD1, and Fer KD2 (Fig. 3B) . Thus, Fer silencing does not regulate growth or survival of H1299 cells.
Because we observed Fer localization within EGF-induced lamellipodia in H1299 cells, we compared the proportion of nontargeting and Fer knockdown cells with prominent leading edge lamellipodia marked by F-actin staining. Following EGF treatment for 5 minutes, Fer knockdown cells appeared less polarized, and had less extensive F-actin-rich membrane ruffles compared with nontargeting control cells (Fig. 3C) . Next, we scored the percentage of cells in these assays with extensive lamellipodia (>50% of cell periphery), and observed significantly fewer Fer knockdown cells with this migratory phenotype compared with nontargeting control ( Fig. 3D ; P < 0.05). Taken together, these results implicate Fer kinase in enhancing EGFR signaling to pathways promoting lamellipodia formation.
Fer phosphorylates Vav2 downstream of EGFR
A recent study reported that overexpression of Fer enhanced tyrosine phosphorylation of the GEF Vav2 and formation of lamellipodia (11) . Because EGF-induced Vav2 pY was shown to enhance its GEF activity toward Rac GTPase (21), we hypothesized that Fer silencing impairs Vav2 pY leading to defects in Rac activation, a key inducer of lamellipodia formation (32) . To test this, serum-starved H1299 nontargeting and Fer knockdown cells were treated with or without EGF for 5 minutes and then harvested. No overt defect in global pY levels was observed in SCLs from Fer knockdown cells compared with nontargeting control (Fig. 4A, top) . EGF treatment led to increased Vav2 pY in both nontargeting and Fer knockdown cells, however, the levels of Vav2 pY were reduced in Fer knockdown cells (Fig.  4A, third panel) . This difference was not due to altered levels or recovery of Vav2 in Fer knockdown cells (Fig. 4A,  bottom) .
To complement these findings, and rule out the possibility of off target effects of our shRNAs, we tested Vav2 pY phosphorylation status in MEF from WT (fer þ/þ ) and homozygous D743R knockin mice (fer DR/DR ) devoid of Fer kinase activity (19) , (20) . MEFs were serum-starved and treated with or without EGF for 5 minutes. As expected, EGF treatment led to increased pY of many prominent proteins in lysates for both genotypes (Fig. 4B, top) Vav2 has 3 tyrosines within an acidic domain, and phosphorylation of these residues leads to enhanced Rac GEF activity (Supplementary Fig. S2A and S2B; ref. 33) . We predicted that Fer may phosphorylate at least one of these sites, due to the observed partial reduction in Vav2 pY in Ferdeficient cells. To address this, we compared Vav2 pY sites with an autophosphorylation site in Fer (Y402), and that of a known Fer substrate (cortactin Y421; refs. 13, 20) . Of the 3 sites in Vav2 acidic domain, Y172 showed some conservation of acidic residues in þ1 and þ2 positions with Fer Y402 and cortactin Y421 (Supplementary Fig. S2C ). To test whether Vav2-Y172 is a target of Fer kinase in NSCLC cells, we subjected lysates from nontargeting, Fer KD1, and KD2 cell treated with EGF for 0 to 15 minutes to immunoblot analyses with pY172-Vav2 antisera. We observed increased Vav2 pY172 within 5 minutes of EGF treatment in nontargeting cells (Fig. 4C) . In contrast, EGF treatment failed to induce detectable Vav2 pY172 in Fer knockdown cells (Fig. 4C) . These results are consistent with Fer promoting Vav2 pY downstream of EGFR, but do not address whether Vav2 is a direct substrate of Fer. To test this, we conducted in vitro kinase assays with purified, active Fer and purified Vav2 N-terminal domain constructs (GST-Vav2 nontargeting) with individual or combined mutations of pY sites to phenylalanine (F) residues (Fig. 4D) . Interestingly, Fer induced Vav2 pY in the WT construct and this was lost in the Y172F-mutant construct (Fig. 4D) . Additional mutations to Y142 and Y159 did not have an effect in this assay (Fig. 4D) , suggesting that Fer specifically phosphorylates Vav2 Y172 in vitro and in NSCLC cells.
Fer promotes EGFR signaling to Rac1 GTPase
Because phosphorylation of Vav2 Y172 enhances GEF activity toward Rac (34) , and Vav2 was hypophosphorylated in Fer knockdown NSCLC cells, we tested for potential differences in Rac GTP levels. H1299 cells (nontargeting, KD1, KD2) were serum-starved and treated with EGF for 5 minutes, and processed for immunofluorescence staining with a Rac1 GTP -specific antibody, along with counterstaining of F-actin and cell nuclei. Subsequent confocal microscopy analysis revealed the expected accumulation of Rac1 GTP (green) within the F-actin (red)-rich lamellipodia in H1299 nontargeting cells treated with EGF (Fig. 5,  see arrows) . In contrast, Fer knockdown cells contained a cytosolic pool of Rac1 GTP , which may reflect the endosomal pool of this protein (35) , and only limited Rac1 GTP at the cell periphery was observed (Fig. 5) . These results are consistent with EGFR signaling leading to activation of a membranetargeted pool of Fer that phosphorylates Vav2 and enhances GTP loading of Rac at leading edge membrane protrusions.
Fer silencing impairs NSCLC cell motility and invasion
Because Rac1 promotes lamellipodia formation and cell motility (36) , and Fer silencing impaired EGFR and Vav2 signaling to Rac1, we tested whether Fer regulates NSCLC cell motility. Initial experiments using a scrape woundinduced cell motility assay, we observed a significant reduction in wound area closure in Fer knockdown cells (55% and 74% reductions in KD1 and KD2, respectively) compared with nontargeting control cells (Supplementary Fig. S3 ). We further tested the effect of Fer knockdown on cell motility using an adapted EGF-embedded agarose drop chemotaxis assay (26) to allow simultaneous analysis of H1299 nontargeting and Fer knockdown cells under identical conditions. Cell lines were cultured with cell permeable fluorescent dyes (nontargeting, red channel; Fer knockdown, green channel) before plating of an equal mixture on poly-L-lysine/ fibronectin-coated coverslips containing an agarose drop enriched with EGF. Time-lapse confocal microscopy was conducted on live cells over 18 hours, and we observed cells around the margin of the agarose drop begin to invade underneath the drop (Fig. 6A and Supplementary Video S1). Compared with nontargeting control cells, we observed fewer Fer knockdown cells migrating under the agarose drop in multiple separate fields of view ( Fig. 6B ; 50% reduction compared with control; P < 0.05). Analysis of cells migrating under the agarose drop revealed a significant reduction in cell migration velocity with Fer silencing (Fig. 6C ; 41% reduction; P < 0.05). To extend on these results, we compared the invasive properties of H1299 nontargeting and Fer knockdown cells after culturing them in Transwell chambers overlayed with Matrigel. We observed a 75% reduction in cell invasion in Fer knockdown cells compared with nontargeting control ( Fig. 6D ; P < 0.05). To test the role of Fer in another NSCLC cell line, we achieved stable Fer silencing in A549 cells and observed similar defects in wound healing migration and cell invasion in Fer knockdown cells compared with nontargeting control (Supplementary Fig. S4 ). Taken together, these results are consistent with an EGFR/ ] were stimulated with EGF (100 ng/mL) for 5 minutes before being harvested and subjected to immunoprecipitation with mouse anti-Vav2 antisera. Immunoprecipitation and SCL fractions were probed with indicated antibodies. C, starved H1299 cells were stimulated with EGF (100 ng/mL) at multiple time points, harvested and probed with phosphotyrosine 172 Vav2 antisera. D, GST cleaved N-terminal fragments of Vav2 with tyrosine to phenylalanine (YF) mutations were subjected to an in vitro kinase assay with ATP and with or without active Fer. To assess phosphorylation, samples were subjected to immunoblot (IB) with mouse antiphosphotyrosine antisera.
Fer/Vav2/Rac pathway that promotes directional migration and invasion in NSCLC cells.
Fer kinase promotes NSCLC metastasis in vivo
To test the in vivo effects of Fer silencing on NSCLC progression and metastasis, we generated subcutaneous tumor xenografts for H1299 nontargeting or Fer knockdown cells in mice lacking NK, B, and T cells (Rag2 À/À : gc À/À ), that were effective to model metastatic disease (37) . At 5 weeks postinjection, mice were sacrificed and primary tumors and several secondary organs were harvested. We observed no significant differences in primary tumor mass in mice injected with nontargeting control cells or Fer knockdown cells ( Fig. 7A ; N ¼ 17 mice/group from 3 separate experiments). To test whether Fer silencing was maintained in vivo, tumor homogenates were prepared and analyzed for Fer expression by immunoblot. We observed reduced levels of Fer in 3 separate tumors from Fer KD1 cells compared with nontargeting control tumors (Fig. 7B) . Because H1299 cells were previously shown to form spontaneous metastases in mice (29, 30) , we screened other organs (e.g., lung, liver, etc.) for GFPexpressing tumor cells. The only tissue in which we consistently observed spontaneous GFP þ metastases was within the lungs (data not shown). Indeed, metastatic nodules were present within lung tissue sections from these mice harboring subcutaneous H1299 tumors (Fig.  7C, see arrows) . Upon analysis of serial lung sections from each mouse, we observed significantly reduced numbers of lung metastases for mice harboring Fer knockdown subcutaneous tumors than those with nontargeting control tumors ( Fig. 7D ; P < 0.05). Together, these results identify an EGFR/Fer/Vav2/Rac signaling axis that promotes metastasis of NSCLC, and suggests that Fer is a potential therapeutic target for metastatic NSCLC.
Discussion
Aberrant EGFR signaling is known to drive a number of NSCLC-promoting tumor growth and invasiveness (1) . In this study, we provide evidence that Fer propagates EGFR signals that enhance cell migration, invasion, and tumor metastasis. EGFR signaling via Fer is facilitated by high level Fer expression in human NSCLC tumors and derived cell lines. In H1299 adenocarcinoma cells, EGFR signaling led to rapid Fer activation and localization to leading edge membrane protrusions. This membrane pool of Fer is functional, as stable silencing of Fer caused defects in EGF-induced lamellipodia formation, cell migration, and invasion. We went on to define Fer substrates and pathways to explain these defects. Because Fer overexpression was shown to enhance Vav2 pY and Rac-dependent lamellipodia formation (11), we tested whether Fer knockdown cells displayed defects in this signaling axis. Indeed, Vav2 was identified as a direct substrate of Fer, with Y172 identified as the preferred site. Because EGF-induced Vav2 pY was previously shown to enhance GEF activity toward Rac (21), our study implicates Fer in participating in this key pathway at leading edge membrane protrusions. Reduced Rac1 signaling to actin nucleation promoting factors (e.g., WAVE) at these sites may explain the defects in H1299 cell migration (reduced velocity and persistence) observed by live cell imaging. Similar results were observed with Fer silencing in A549 NSCLC cells, which displayed reduced motility and cell invasion. The significance of these defects observed using in vitro assays was tested by conducting tumor xenograft assays in mice using control and Fer knockdown H1299 cells. We observed no effects of Fer silencing on growth of subcutaneous NSCLC tumors, but a significant defect in numbers of spontaneous lung metastases. Taken together, these findings identify Fer as a key mediator of EGFR signaling in NSCLC that enhances tissue invasion and metastasis pathways. EGFR-induced Fer activation and downstream signaling is likely to involve more than the direct interaction of these proteins, such as production of second messengers that attract Fer and its substrates to the plasma membrane. EGFR activation is known to activate PLD and enhance phosphatidic acid levels in membrane microdomains (31) . It is worth noting that both the F-BAR/FX of Fer and the poly-basic C domain of Rac1 bind to phosphatidic acid, leading to Fer activation and reduced Rac1 sequestration by RhoGDIa (11), (38) , (39) . Fer can also phosphorylate RhoGDIa directly to limit Rac1 binding (22) . Along with enhanced Vav2 pY, this may also contribute to the ability of Fer to enhance Rac1 GTP at the leading edge protrusions in NSCLC cells (this article).
Fer phosphorylates multiple substrates linked to the regulation of actin polymerization. One of these proteins is the actin branching protein cortactin, which is phosphorylated by Fer in response to integrin-induced reactive oxygen species and F-actin depolymerization (20) , (40) . Defects in cortactin pY may also contribute to the defects in actin-based motility in Fer knockdown NSCLC cells, although no consistent defects in cortactin pY were observed in Fer knockdown H1299 cells (data not shown). However, we do provide evidence for a Fer-mediated Vav2/Rac pathway that enhances F-actin branching and cell motility via activation of WAVE-Arp2/3 complex and inhibition of F-actin severing by cofilin (41), (42) . These findings suggest that Fer signals through multiple actin polymerization pathways to ultimately promote cell migration and invasion.
Although Fer pY was identified in proteomic studies of lung cancer (14) , there have been limited studies of Fer function in lung cancer. In addition to our findings linking Fer to NSCLC cell invasion and tumor metastasis, it will be important to further characterize potential roles of Fer in regulating key transcription factors linked to cancer progression and resistance to potential cancer therapies. Recently, an insertional mutagenesis screen led to the discovery that Fer overexpression confers resistance to quinacrine-induced cell death via enhancing EGFR signaling to NF-kB (5). Thus, it will be important to test whether Fer knockdown NSCLC cells display defects in NF-kB target genes that may contribute to NSCLC metastasis. These include NF-kB-induced cell adhesion proteins linked to chemotherapy resistance and lung cancer metastasis (43, 44) . Another recent study identified a Fer/STAT3 pathway that represses expression of laminin binding glycans and glycosyltransferases (e.g., LARGE) that inhibit the motility of carcinomas (45) . These glycans regulate airway wound-healing responses (46) . Loss of laminin binding in lung cancers was recently shown to involve downregulation of LARGE, and migration was inhibited following ectopic expression of LARGE (47) . In future studies, it will be worth testing whether Fer regulates airway wound-healing responses or NSCLC metastasis via the STAT3 pathway. Although this study was under review, another group reported that Fer overexpression is associated with poor prognosis in patients with NSCLC that had undergone surgery, and this association was independent of tumor stage, treatment regimen, or EGFR status (48) . Together with our results implicating Fer in promoting NSCLC metastasis, this lends further support to pursuing Fer as a therapeutic target in NSCLC.
Fer is likely to promote the progression or metastasis in other cancer types as well as lung cancer. Recently, Fer was shown to promote prostate cancer progression via an IL-6/ Fer/STAT3 pathway (16) . Increased Fer phosphorylation has also been observed in metastatic hepatocellular carcinomas (15) and highly metastatic breast cancers (17) . Because Fer-deficient mice have no overt phenotypes (19) , it is likely to be a drugable target. It is also promising that several inhibitors of Fes kinase were recently identified and used to inhibit osteoclast differentiation (49) . On the basis of their high degree of homology, it is likely that at least a subset of Fes inhibitors are also Fer inhibitors, and this will be worth testing in future using preclinical models of metastatic lung cancer and other relevant cancer models. In conclusion, Fer is an emerging therapeutic target to develop additional antimetastasis treatment regimens.
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